NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Capital Expenditures of $38000.0 for Q1 2026, up 137.5% on a YoY basis from $16000.0 in Q1 2025, and down 62.0% sequentially from $100000.0 in Q4 2025.
NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Capital Expenditures data on file, last reported at $38000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 137.5% year-over-year to $38000.0; the trailing twelve-month figure through Mar 2026 stood at $268000.0 (down 11.55% YoY), and the FY2025 full-year result was $246000.0, down 63.39% from the prior year.
- Capital Expenditures fell to $38000.0 in Q1 2026, from $100000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $385000.0 in Q1 2024 to a low of $3000.0 in Q4 2023.
- A 4-year average of $75384.6 and a median of $38000.0 in 2026 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 5400.0% in 2024 and plunged 95.84% in 2025, its largest moves.
- Tracing NAMS's Capital Expenditures over 4 years: stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then soared by 3233.33% to $100000.0 in 2025, then sank by 62.0% to $38000.0 in 2026.
- Business Quant data shows NAMS's Capital Expenditures at $38000.0 in Q1 2026, $100000.0 in Q4 2025, and $42000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | 38,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38,000.00 |
| Mar 31, 2026 | 38,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |